Author:

Keywords:

Science & Technology, Life Sciences & Biomedicine, Gastroenterology & Hepatology, ACTIVE CROHNS-DISEASE, PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY, MONOCLONAL-ANTIBODY ADALIMUMAB, ANTIINTERFERON-GAMMA ANTIBODY, CASPASE-DEPENDENT PATHWAY, PLACEBO-CONTROLLED TRIAL, PROPRIA T-LYMPHOCYTES, NECROSIS-FACTOR-ALPHA, ULCERATIVE-COLITIS, DOUBLE-BLIND, Anti-Inflammatory Agents, Antigens, CD, Autoantibodies, Biological Therapy, Cell Adhesion Molecules, Cytokines, Gastrointestinal Agents, Humans, Immunity, Innate, Inflammatory Bowel Diseases, Intestinal Mucosa, Receptors, Cytokine, 1103 Clinical Sciences, 3202 Clinical sciences

Abstract:

Anti-TNF antibodies were the first biologic agents registered to treat patients who have CD and, more recently, patients who have UC. The sequence of events underlying the inflammatory reaction in IBD is extremely complex, however, and involves both the innate and antigen-driven adaptive immune system. Novel therapies are directed at several key players of this cascade. Blockade of T-cell proliferation and activation and inhibition of T-cell cytokines has been most extensively targeted by clinical trials in humans. Inhibition of adhesion molecules and the use of selected growth factors seem to have therapeutic potential. Restoration of regulatory T-cell and dendritic-cell function is still waiting to be explored in clinical trials. Although an increasing number of biologic therapies for IBD are being developed, the discovery of the full spectrum of treatment modalities is only beginning. Often, however, the clinical efficacy of biologic agents is investigated, and for some molecules is established, before mechanisms of action are specifically explored. Eight years after the Food and Drug Administration approved infliximab for the treatment of luminal CD, it is not known how this anti-TNF antibody actually dampens inflammation in IBD. The advent of newer anti-TNF agents is only postponing the answer.